US equities |
MU $973.48 ▲+4.81% META $612.82 ▼-1.19% TSLA $401.50 ▼-1.46% SPCX $144.33 ▼-2.86% SNDK $1,377.26 ▲+5.55% NVDA $217.93 ▼-0.00% SKHY $163.13 ▲+12.23% STX $674.66 ▲+1.02%
FinancialContent

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

5.190 +0.110 (+2.17%)
Delayed Quote Updated: 11:22 AM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Gainers Brickell Biotech (NASDAQ:BBI) stoc... 
Via Benzinga
News headline image
Want to Buy CNS Pharmaceuticals (NASDAQ: CNSP) Stock? Read This First. ↗
CNS Pharmaceuticals (NASDAQ: CNSP) is a pre-clinical biotech company focusing on treatments for brain tumors. The firm holds the exclusive worldwide license for its main... 
Via Benzinga
Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027
Via FinancialNewsMedia
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
Via FinancialNewsMedia
FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
Via FinancialNewsMedia
News headline image
CNS Pharmaceuticals Begins Enrollment, Screening Brain Cancer Study With Berubicin ↗
CNS Pharmaceuticals Inc (NASDAQ: CNSP) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma... 
Via Benzinga
News headline image
CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin ↗
CNS Pharmaceuticals today announced open enrollment for its potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM. 
Via Talk Markets
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >